Banque Cantonale Vaudoise Has $1.94 Million Position in IQVIA Holdings Inc. $IQV

Banque Cantonale Vaudoise grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 51.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,192 shares of the medical research company’s stock after buying an additional 3,451 shares during the quarter. Banque Cantonale Vaudoise’s holdings in IQVIA were worth $1,936,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Artisan Partners Limited Partnership acquired a new position in IQVIA in the 2nd quarter worth about $515,772,000. Norges Bank acquired a new stake in shares of IQVIA during the second quarter valued at about $270,160,000. AQR Capital Management LLC boosted its stake in shares of IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares in the last quarter. Laurel Wealth Advisors LLC grew its holdings in shares of IQVIA by 15,755.2% during the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after purchasing an additional 774,681 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of IQVIA by 22.8% in the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after buying an additional 581,157 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Mizuho set a $215.00 price target on shares of IQVIA in a research note on Monday, February 23rd. Jefferies Financial Group decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Truist Financial reduced their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Finally, BMO Capital Markets set a $250.00 price target on IQVIA in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $229.13.

IQVIA Trading Up 0.4%

IQV opened at $171.64 on Thursday. The company has a fifty day moving average price of $204.05 and a two-hundred day moving average price of $207.14. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a market cap of $29.13 billion, a P/E ratio of 21.84, a price-to-earnings-growth ratio of 1.65 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same period last year, the business earned $3.12 EPS. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.